RecruitingPhase 1NCT07222267

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

Sponsor

BeOne Medicines

Enrollment

86 participants

Start Date

Dec 11, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Advanced Solid Tumor

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This early-phase study is testing a new investigational drug called BG-75202 — alone or with other treatments — in adults with advanced solid tumors or lymphomas that have not responded to standard therapies. Different parts of the study target different patient populations with advanced breast cancer or other solid tumors. **You may be eligible if...** - You are 18 or older - You have advanced, metastatic breast cancer or other solid tumors that no longer respond to standard treatment - Earlier phases may require you to have had 1-3 prior treatment lines in the metastatic setting - Certain phases target patients who have not yet received CDK4/6 inhibitor therapy **You may NOT be eligible if...** - You have had more prior lines of chemotherapy than the study allows for your specific cohort - Your cancer type is not eligible for the specific phase you qualify for - You have untreated brain metastases or serious other medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBG-75202

Administered orally.

DRUGCDK4 Inhibitor

Administered orally.

DRUGEstrogen Receptor Antagonist

Administered by intramuscular injection.

DRUGAromatase Inhibitor

Administered orally.

Locations(23)

University of Alabama At Birmingham Hospital

Birmingham, Alabama, United States

Yale Cancer Center

New Haven, Connecticut, United States

Washington University in St Louis

St Louis, Missouri, United States

Next Oncology Austin

Austin, Texas, United States

The University of Texas Md Anderson Cancer Center

Houston, Texas, United States

Blacktown Cancer and Haematology Centre

Blacktown, New South Wales, Australia

Chris Obrien Lifehouse

Camperdown, New South Wales, Australia

Cancer Research South Australia

Adelaide, South Australia, Australia

Peter Maccallum Cancer Centre

Melbourne, Victoria, Australia

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Sun Yat Sen University Cancer Centerhuangpu Branch

Guangzhou, Guangdong, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Jiangsu Province Hospital Longjiang Branch

Nanjing, Jiangsu, China

Fudan University Shanghai Cancer Centerpudong

Shanghai, Shanghai Municipality, China

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

Istituto Europeo Di Oncologia

Milan, Italy

Fondazione Policlinico Universitario Agostino Gemelli

Roma, Italy

Istituto Clinico Humanitas

Rozzano, Italy

Next Oncology Barcelona

Barcelona, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Clinico San Carlos

Madrid, Spain

Hospital Universitario Virgen de La Victoria

Málaga, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07222267

Related Trials

Genomic Services Research Program

NCT025959571 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT070671381 location

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations